Top

Pediatric Drugs

Published in:

Open Access 03-06-2023 | Pulmonary Hypertension | Original Research Article

Macitentan in the Young—Mid-term Outcomes of Patients with Pulmonary Hypertensive Vascular Disease treated in a Pediatric Tertiary Care Center

Authors: Sulaima Albinni, Julian Heno, Imre Pavo, Erwin Kitzmueller, Manfred Marx, Ina Michel-Behnke

Published in: Pediatric Drugs | Issue 4/2023

Abstract

Background

Pulmonary hypertension (PH) is a severe hemodynamic condition with high morbidity and mortality. Approved targeted therapies are limited for pediatric subjects, and treatments are widely adopted from adult algorithms. Macitentan is a safe and effective drug used for adult PH, but data on pediatric patients are limited. In this prospective single-center study, we investigated mid- and long-term effects of macitentan in children with advanced pulmonary hypertensive vascular disease.

Methods

Twenty-four patients were enrolled in the study for treatment with macitentan. Efficacy was determined by echo parameters and brain natriuretic peptide levels (BNP) at 3 months and 1 year. For detailed analysis, the entire cohort was subgrouped into patients with congenital heart disease-related PH (CHD-PH) and non-CHD-PH patients, respectively.

Results

Mean age of the patients was 10.7 ± 7.6 years; median observation period was 36 months. Twenty of 24 patients were on additional sildenafil and/or prostacyclins. Two of 24 patients discontinued because of peripheral edema.

Within the entire cohort, BNP levels and all echo measures such as right ventricular systolic pressure (RVSP), right ventricular end-diastolic diameter (RVED), tricuspid annular plane systolic excursion (TAPSE), pulmonary velocity time integral (VTI), and pulmonary artery acceleration time (PAAT) improved significantly after 3 months (p ≤ 0.01), whereas in the long term significant improvement persisted for BNP levels (−16%), VTI (+14%) and PAAT (+11%) (p < 0.05). By subgroup analysis, non-CHD PH patients showed significant improvements in BNP levels (−57%) and all echo measures (TAPSE +21%, VTI +13%, PAAT +37%, RVSP −24%, RVED −12%) at 3 months (p ≤ 0.01), whereas at 12 months, improvements persisted (p < 0.05) except for RVSP and RVED (nonsignificant). In CHD-PH patients, none of the measures changed (nonsignificant). 6-MWD (distance walked in 6 minutes) slightly increased but was not statistically evaluated.

Conclusion

Data presented herein account for the largest cohort of severely affected pediatric patients receiving macitentan. Overall, macitentan was safe and associated with significant beneficial effects and sustained positive signals after 1 year, albeit in the long term disease progression remains a major concern. Our data suggest limited efficacy in CHD-related PH, whereas favorable outcomes were mainly driven by improvements in patients with PH not related to CHD. Larger studies are needed to verify these preliminary results and to prove efficacy of this drug in different pediatric PH entities.

Available only for authorised users

Rosenzweig EB, Abman SH, Adatia I, Beghetti M, Bonnet D, Haworth S, et al. Paediatric pulmonary arterial hypertension: updates on definition, classification, diagnostics and management. Eur Respir J [Internet]. 2019;53:1801916. https://doi.org/10.1183/13993003.01916-2018.CrossRefPubMedPubMedCentral

Berger RM, Beghetti M, Humpl T, et al. Clinical features of paediatric pulmonary hypertension: a registry study. Lancet. 2012;379(9815):537–546. https://doi.org/10.1016/S0140-6736(11)61621-8. Accessed 30 Sept 2022.

Hansmann G, Koestenberger M, Alastalo T-P, Apitz C, Austin ED, Bonnet D, et al. 2019 updated consensus statement on the diagnosis and treatment of pediatric pulmonary hypertension: The European Pediatric Pulmonary Vascular Disease Network (EPPVDN), endorsed by AEPC, ESPR and ISHLT. J Heart Lung Transplant Off Publ Int Soc Heart Transplant. 2019;38:879–901.CrossRef

Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: Developed by the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Endorsed by the International Society for Heart and Lung Transplantation (ISHLT) and the European Reference Network on rare respiratory diseases (ERN-LUNG). Eur Heart J [Internet]. 2022. https://doi.org/10.1093/eurheartj/ehac237.CrossRefPubMed

del Cerro MJ, Abman S, Diaz G, Freudenthal AH, Freudenthal F, Harikrishnan S, et al. A consensus approach to the classification of pediatric pulmonary hypertensive vascular disease: report from the PVRI Pediatric Taskforce, Panama 2011. Pulm Circ. 2011;1:286–98. https://doi.org/10.4103/2045-8932.83456.CrossRefPubMedPubMedCentral

Tuder RM, Archer SL, Peter D, Erzurum SC, Christophe G, Evangelos M, et al. Relevant issues in the pathology and pathobiology of pulmonary hypertension. J Am Coll Cardiol. 2013;62:D4-12. https://doi.org/10.1016/j.jacc.2013.10.025.CrossRefPubMedPubMedCentral

Lang IM, Bonderman D, Kneussl M, Marx M. Paediatric pulmonary vascular disease. Paediatr Respir Rev [Internet]. 2004 [cited 2019 Apr 13];5:238–48. https://linkinghub.elsevier.com/retrieve/pii/S152605420400048X.

Zijlstra WMH, Douwes JM, Rosenzweig EB, Schokker S, Krishnan U, Roofthooft MTR, et al. Survival differences in pediatric pulmonary arterial hypertension: clues to a better understanding of outcome and optimal treatment strategies. J Am Coll Cardiol. 2014;63:2159–69.CrossRefPubMed

Moledina S, Hislop AA, Foster H, Schulze-Neick I, Haworth SG. Childhood idiopathic pulmonary arterial hypertension: a national cohort study. Heart [Internet]. 2010;96:1401–6. https://doi.org/10.1136/hrt.2009.182378.CrossRefPubMed

10.

Beghetti M. Current treatment options in children with pulmonary arterial hypertension and experiences with oral bosentan. Eur J Clin Invest. 2006;36(Suppl 3):16–24.CrossRefPubMed

11.

Avitabile CM, Vorhies EE, Ivy DD. Drug treatment of pulmonary hypertension in children. Paediatr Drugs. 2020;22:123–47.CrossRefPubMedPubMedCentral

12.

Galiè N, Humbert M, Vachiery J-L, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS)Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J [Internet]. 2016;37:67–119. https://doi.org/10.1093/eurheartj/ehv317.CrossRefPubMed

13.

Pulido T, Adzerikho I, Channick RN, Delcroix M, Galiè N, Ghofrani H-A, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med [Internet]. 2013;369:809–18. https://doi.org/10.1056/NEJMoa1213917.CrossRefPubMed

14.

Dingemanse J, Sidharta PN, Maddrey WC, Rubin LJ, Mickail H. Efficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertension. Expert Opin Drug Saf [Internet]. 2014;13:391–405. https://doi.org/10.1517/14740338.2014.859674.CrossRefPubMed

15.

Iglarz M, Binkert C, Morrison K, Fischli W, Gatfield J, Treiber A, et al. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J Pharmacol Exp Ther [Internet]. 2008;327:736–45. https://doi.org/10.1124/jpet.108.142976.CrossRefPubMed

16.

Aypar E, Alehan D, Karagöz T, Aykan HH, Ertugrul İ. Clinical efficacy and safety of switch from bosentan to macitentan in children and young adults with pulmonary arterial hypertension. Cardiol Young [Internet]. 2018;28:542–7. https://www.cambridge.org/core/product/identifier/S1047951117002542/type/journal_article. Accessed 20 April 2022.

17.

Flores M, Caro AT, Mendoza A. Initial experience in children with the use of macitentan in pulmonary arterial hypertension after side effects with other endothelin receptor antagonists. Prog Pediatr Cardiol [Internet]. 2019;52:55–6. http://www.sciencedirect.com/science/article/pii/S1058981318300341. Accessed 20 April 2022

18.

Safdar Z, Thakur A, Frost A. Tolerability of switch to macitentan from bosentan in pulmonary arterial hypertension. South Med J [Internet]. 2017;110:223–8. http://sma.org/southern-medical-journal/article/tolerability-switch-macitentan-bosentan-pulmonary-arterial-hypertension. Accessed 20 April 2022

19.

Schweintzger S, Koestenberger M, Schlagenhauf A, Grangl G, Burmas A, Kurath-Koller S, et al. Safety and efficacy of the endothelin receptor antagonist macitentan in pediatric pulmonary hypertension. Cardiovasc Diagn Ther. 2020;10:1675–85.CrossRefPubMedPubMedCentral

20.

Albinni S, Pavo I, Kitzmueller E, Michel-Behnke I. Macitentan in infants and children with pulmonary hypertensive vascular disease. Feasibility, tolerability and practical issues – a single-centre experience. Pulm Circ. 2021;11:2045894020979503. https://doi.org/10.1177/2045894020979503.CrossRefPubMedPubMedCentral

21.

Ross RD. The Ross classification for heart failure in children after 25 years: a review and an age-stratified revision. Pediatr Cardiol. 2012;33:1295–300.CrossRefPubMed

22.

Nafiu OO, Voepel-Lewis T, Morris M, Chimbira WT, Malviya S, Reynolds PI, et al. How do pediatric anesthesiologists define intraoperative hypotension? Paediatr Anaesth. 2009;19:1048–53.CrossRefPubMed

23.

Forfia PR, Fisher MR, Mathai SC, Housten-Harris T, Hemnes AR, Borlaug BA, et al. Tricuspid annular displacement predicts survival in pulmonary hypertension. Am J Respir Crit Care Med [Internet]. 2006;174:1034–41. https://doi.org/10.1164/rccm.200604-547OC.CrossRefPubMed

24.

Koestenberger M, Ravekes W, Everett AD, Stueger HP, Heinzl B, Gamillscheg A, et al. right ventricular function in infants, children and adolescents: reference values of the tricuspid annular plane systolic excursion (TAPSE) in 640 healthy patients and calculation of z score values. J Am Soc Echocardiogr [Internet]. 2009;22:715–9. https://linkinghub.elsevier.com/retrieve/pii/S0894731709003083. Accessed 20 Oct 2022

25.

Abbas AE, Franey LM, Marwick T, Maeder MT, Kaye DM, Vlahos AP, et al. Noninvasive assessment of pulmonary vascular resistance by Doppler echocardiography. J Am Soc Echocardiogr [Internet]. 2013;26:1170–7. https://www.sciencedirect.com/science/article/pii/S0894731713004458. Accessed 20 Oct 2022

26.

Arkles JS, Opotowsky AR, Ojeda J, Rogers F, Liu T, Prassana V, et al. Shape of the right ventricular Doppler envelope predicts hemodynamics and right heart function in pulmonary hypertension. Am J Respir Crit Care Med. 2011;183:268–76.CrossRefPubMed

27.

Opotowsky AR, Clair M, Afilalo J, Landzberg MJ, Waxman AB, Moko L, et al. A Simple echocardiographic method to estimate pulmonary vascular resistance. Am J Cardiol [Internet]. 2013;112:873–82. https://linkinghub.elsevier.com/retrieve/pii/S0002914913011296. Accessed 20 Oct 2022

28.

Lammers AE, Apitz C, Michel-Behnke I, Koestenberger M. A guide to echocardiographic assessment in children and adolescents with pulmonary hypertension. Cardiovasc Diagn Ther. 2021;11:1160–77.CrossRefPubMedPubMedCentral

29.

Chemla D, Castelain V, Humbert M, Hébert J-L, Simonneau G, Lecarpentier Y, et al. New formula for predicting mean pulmonary artery pressure using systolic pulmonary artery pressure. Chest [Internet]. 2004 [cited 2022 Apr 10];126:1313–7. https://linkinghub.elsevier.com/retrieve/pii/S001236921531312X.

30.

Steckelberg RC, Tseng AS, Nishimura R, Ommen S, Sorajja P. Derivation of mean pulmonary artery pressure from noninvasive parameters. J Am Soc Echocardiogr Off Publ Am Soc Echocardiogr. 2013;26:464–8.CrossRef

31.

Galiè N, Jansa P, Pulido T, Channick RN, Delcroix M, Ghofrani H-A, et al. SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension. Eur Heart J. 2017;38:1147–55. Accessed 12 Dec 2022CrossRefPubMedPubMedCentral

32.

Aypar E, Alehan D, Karagöz T, Aykan H, Ertugrul İ. Clinical efficacy and safety of switch from bosentan to macitentan in children and young adults with pulmonary arterial hypertension: extended study results. Cardiol Young [Internet]. 2020;30:681–5. https://www.cambridge.org/core/product/identifier/S1047951120000773/type/journal_article.

33.

López-Candales A, Edelman K. Shape of the right ventricular outflow Doppler envelope and severity of pulmonary hypertension. Eur Heart J Cardiovasc Imaging [Internet]. 2012;13:309–16. https://doi.org/10.1093/ejechocard/jer235.CrossRefPubMed

34.

Nadeau V, Potus F, Boucherat O, Paradis R, Tremblay E, Iglarz M, et al. Dual ETA/ETB blockade with macitentan improves both vascular remodeling and angiogenesis in pulmonary arterial hypertension. Pulm Circ. 2018;8:2045893217741429.CrossRefPubMed

35.

Langleben D, Orfanos SE, Fox BD, Messas N, Giovinazzo M, Catravas JD. The paradox of pulmonary vascular resistance: restoration of pulmonary capillary recruitment as a sine qua non for true therapeutic success in pulmonary arterial hypertension. J Clin Med [Internet]. 2022;11:4568. https://www.mdpi.com/2077-0383/11/15/4568.

36.

Brittain EL, Pugh ME, Wheeler LA, Robbins IM, Loyd JE, Newman JH, et al. Prostanoids but not oral therapies improve right ventricular function in pulmonary arterial hypertension. JACC Heart Fail [Internet]. 2013;1:300–7. https://www.sciencedirect.com/science/article/pii/S2213177913001893. Accessed 12 Dec 2022

37.

Iglarz M, Landskroner K, Bauer Y, Vercauteren M, Rey M, Renault B, et al. Comparison of macitentan and bosentan on right ventricular remodeling in a rat model of non-vasoreactive pulmonary hypertension. J Cardiovasc Pharmacol. 2015;66:457.CrossRefPubMedPubMedCentral

38.

Anton VN, Richard C, Emmanuelle C, Kiely David G, Tim MJ, Nicolas M, et al. The REPAIR Study. JACC Cardiovasc Imaging [Internet]. 2022;15:240–53. https://doi.org/10.1016/j.jcmg.2021.07.027.CrossRef

39.

Rosenzweig EB, Ivy DD, Widlitz A, Doran A, Claussen LR, Yung D, et al. Effects of long-term bosentan in children with pulmonary arterial hypertension. J Am Coll Cardiol [Internet]. 2005 [cited 2019 Apr 13];46:697–704. https://linkinghub.elsevier.com/retrieve/pii/S0735109705011964.

40.

Gatzoulis MA, Beghetti M, Galiè N, Granton J, Berger RMF, Lauer A, et al. Longer-term bosentan therapy improves functional capacity in Eisenmenger syndrome: results of the BREATHE-5 open-label extension study. Int J Cardiol. 2008;127:27–32. Accessed 10 April 2022CrossRefPubMed

41.

Apostolopoulou SC, Manginas A, Cokkinos DV, Rammos S. Long-term oral bosentan treatment in patients with pulmonary arterial hypertension related to congenital heart disease: a 2-year study. Heart [Internet]. 2007;93:350–4. https://doi.org/10.1136/hrt.2006.100388.CrossRefPubMed

42.

Arnott C, Strange G, Bullock A, Kirby AC, O’Donnell C, Radford DJ, et al. Pulmonary vasodilator therapy is associated with greater survival in Eisenmenger syndrome. Heart [Internet]. 2018;104:732–7. https://doi.org/10.1136/heartjnl-2017-311876.CrossRef

43.

Barst RJ, Ivy D, Dingemanse J, Widlitz A, Schmitt K, Doran A, et al. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin Pharmacol Ther. 2003;73:372–82.CrossRefPubMed

44.

Wacker J, Weintraub RG. Macitentan in pulmonary arterial hypertension associated with congenital heart defects. Heart Lung Circ [Internet]. 2017;26:1006–7. https://linkinghub.elsevier.com/retrieve/pii/S1443950617313318.

45.

Herbert S, Gin-Sing W, Howard L, Tulloh RMR. Early Experience of macitentan for pulmonary arterial hypertension in adult congenital heart disease. Heart Lung Circ [Internet]. 2017;26:1113–6. https://linkinghub.elsevier.com/retrieve/pii/S1443950617300318.

46.

Blok IM, van Riel ACMJ, van Dijk APJ, Mulder BJM, Bouma BJ. From bosentan to macitentan for pulmonary arterial hypertension and adult congenital heart disease: Further improvement? Int J Cardiol [Internet]. 2017;227:51–2. https://linkinghub.elsevier.com/retrieve/pii/S0167527316336907

47.

Gatzoulis MA, Landzberg M, Beghetti M, Berger RM, Efficace M, Gesang S, et al. Evaluation of macitentan in patients with Eisenmenger syndrome: results from the randomized, controlled MAESTRO Study. Circulation [Internet]. 2019;139:51–63. https://doi.org/10.1161/CIRCULATIONAHA.118.033575.CrossRefPubMed

48.

Beghetti M, Berger RMF. The challenges in paediatric pulmonary arterial hypertension. Eur Respir Rev [Internet]. 2014;23:498–504. https://doi.org/10.1183/09059180.00007714. Accessed 08 May 2022 CrossRefPubMed

49.

Beghetti M. Bosentan in pediatric patients with pulmonary arterial hypertension. Curr Vasc Pharmacol. 2009;7:225–33. Accessed 08 May 2022CrossRefPubMed

50.

Ivy DD, Abman SH, Barst RJ, Berger RMF, Bonnet D, Fleming TR, et al. Pediatric pulmonary hypertension. J Am Coll Cardiol [Internet]. 2013;62:D117–26. https://linkinghub.elsevier.com/retrieve/pii/S0735109713058713. Accessed 18 Mar 2023

51.

Hislop AA, Moledina S, Foster H, Schulze-Neick I, Haworth SG. Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children. Eur Respir J [Internet]. 2011;38:70–7. https://doi.org/10.1183/09031936.00053510.CrossRefPubMed

52.

Yamamura K, Nagata H, Ikeda K, Ihara K, Hara T. Efficacy of bosentan therapy for segmental pulmonary artery hypertension due to major aortopulmonary collateral arteries in children. Int J Cardiol [Internet]. 2012;161:e1–3. https://linkinghub.elsevier.com/retrieve/pii/S0167527312002264.

53.

Grant EK, Berger JT. Use of pulmonary hypertension medications in patients with tetralogy of fallot with pulmonary atresia and multiple aortopulmonary collaterals. Pediatr Cardiol [Internet]. 2016;37:304–12. https://doi.org/10.1007/s00246-015-1278-2.CrossRefPubMed

54.

Schuuring MJ, Bouma BJ, Cordina R, Gatzoulis MA, Budts W, Mullen MP, et al. Treatment of segmental pulmonary artery hypertension in adults with congenital heart disease. Int J Cardiol [Internet]. 2013;164:106–10. https://linkinghub.elsevier.com/retrieve/pii/S0167527311006243. Accessed 04 Nov 2022

55.

Apostolopoulou SC, Vagenakis G, Rammos S. Pulmonary vasodilator therapy in tetralogy of Fallot with pulmonary atresia and major aortopulmonary collaterals: case series and review of literature. Cardiol Young. 2017;27:1861–4.CrossRefPubMed

56.

Cerro MJ, Moledina S, Haworth SG, Ivy D, Dabbagh MA, Banjar H, et al. Cardiac catheterization in children with pulmonary hypertensive vascular disease: consensus statement from the pulmonary vascular research institute, pediatric and congenital heart disease task forces. Pulm Circ [Internet]. 2016;6:118–25. https://doi.org/10.1086/685102. Accessed 20 Nov 2022CrossRefPubMed

Title: Macitentan in the Young—Mid-term Outcomes of Patients with Pulmonary Hypertensive Vascular Disease treated in a Pediatric Tertiary Care Center
Authors: Sulaima Albinni
Julian Heno
Imre Pavo
Erwin Kitzmueller
Manfred Marx
Ina Michel-Behnke
Publication date: 03-06-2023
Publisher: Springer International Publishing
Keywords: Pulmonary Hypertension
Pulmonary Hypertension
Pulmonary Hypertension
Pulmonary Hypertension
Published in: Pediatric Drugs / Issue 4/2023
Print ISSN: 1174-5878
Electronic ISSN: 1179-2019
DOI: https://doi.org/10.1007/s40272-023-00573-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Macitentan in the Young—Mid-term Outcomes of Patients with Pulmonary Hypertensive Vascular Disease treated in a Pediatric Tertiary Care Center

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2023

Thromboprophylaxis for Coagulopathy Related to COVID-19 in Pediatrics: A Narrative Review

Pharmacokinetics in Critically Ill Children with Acute Kidney Injury

Pitolisant: Pediatric First Approval

Treatment of Langerhans Cell Histiocytosis and Histiocytic Disorders: A Focus on MAPK Pathway Inhibitors

Diagnosis and Management of Pediatric Chronic Hand Eczema: The PeDRA CACHES Survey

Ewing Sarcoma Drug Therapy: Current Standard of Care and Emerging Agents